Recent 8-K filings for NVCR

• Apr 30, 2026 23:59 UTC earnings materiality 0.75 positive item 2.02item 9.01

  Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch

  Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.

• Mar 26, 2026 23:59 UTC other_material materiality 0.75 positive item 7.01item 9.01

  Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC

  PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.

• Feb 26, 2026 23:59 UTC other_material materiality 0.80 positive item 2.02item 9.01

  Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer

  FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.

• Feb 24, 2026 23:59 UTC regulatory materiality 0.60 positive item 7.01item 9.01

  CMS rescinds retroactive revocation of Novocure's Medicare billing privileges

  CMS revoked billing privileges retroactive to Dec 17, 2025; cited administrative re-validation issue, not substantive failure.

• Feb 11, 2026 23:59 UTC regulatory materiality 0.85 positive item 7.01item 9.01

  FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer

  FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.

• Feb 05, 2026 23:59 UTC regulatory materiality 0.85 negative item 7.01item 9.01

  NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement

  CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.

• Jan 12, 2026 23:59 UTC earnings materiality 0.75 positive item 2.02item 9.01

  NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO

  Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).

• Dec 01, 2025 23:59 UTC leadership materiality 0.65 neutral item 5.02item 7.01item 9.01

  Novocure appoints President Frank Leonard as CEO; Ashley Cordova resigns

  Ashley Cordova resigned as CEO and director effective Nov 30, 2025; no disagreement related to operations.

• Oct 30, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review

  Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.

• Sep 15, 2025 23:59 UTC regulatory materiality 0.75 positive item 7.01item 9.01

  Japan MHLW approves Novocure's Optune Lua for advanced NSCLC

  Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.

• Jul 24, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3

  Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.

• Jun 02, 2025 23:59 UTC other_material materiality 0.85 positive item 7.01item 9.01

  Phase 3 PANOVA-3 trial meets primary endpoint; median OS improved to 16.2 vs 14.2 months (HR 0.82, p=0.039)

  Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event other_material

8 positive 1 negative 7 neutral

source · NVCR on sec.gov